[Campath-1H--a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia].
Treatment with antibodies in patients with lymphoproliferative diseases was, until recently, limited to phase I studies due to limited response or subsequent development of anti-globulin response. The introduction of the hybridoma technique during the 1970s facilitated large scale production of antibodies, including the development of the Campath rat-antibodies. The epitope was launched against CD52, a glycoprotein present in large amounts on the surface of lymphocytes, and the primary use was in-vitro depletion of bone marrow from allogeneic bone marrow transplantation donors. The development of the human Campath-1H antibody was successful in 1988, leading to minimized anti-globulin response when used in vivo, and large multi-center studies were initiated. In this study we present an overview of the preclinical and clinical experiences with Campath-1H, including data from patients treated with the antibody in our clinic.
de Nully Brown
P
P
H:S Rigshospitalet, haematologisk afdeling L. 4042.
Hansen
M M
MM
Nissen
N I
NI
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab
Campath-1H--et monoklonalt antistof til behandling af non-Hodgkin-lymfom og kronisk lymfatisk leukaemi.